Latest Forum Topics / Biosensors | Post Reply |
Is Biosensors a good buy?
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AK_Francis
Supreme |
01-Apr-2008 01:52
Yells: "Happy go lucky, cheers." |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Last yrly result announcement was on 25 May 07. This yr the period should be around the same period, Share Investment Handbook(31 Mar 08-13 Apr 08) claimed. Just watch out folks. My view is that if DJ performs well in the coming week, then it is not a bad time to keep some or doing averaging, if could hv acquired some last yr. Cheers. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
01-Apr-2008 01:05
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries Saturday March 29, 9:00 am ET NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX - News) today announced results from an analysis of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to assess the performance of the TAXUS® Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The one-year pooled ARRIVE data confirmed the known higher mortality rate for diabetics versus non-diabetics with cardiovascular disease(1), but showed that the TAXUS Stent had similarly low rates of stent-related cardiac death, myocardial infarction (MI), stent thrombosis, and major cardiac events (MCE) across those two patient subsets. The study also showed similar rates of target vessel re-intervention (TVR) and TAXUS-related TVR in indicated patients(2) per the European Union (EU) label, whether or not they had diabetes. Analysis of the data was presented by D. Lynn Morris, M.D., at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.
The pooled analysis included one-year data on 1,530 medication-requiring diabetic patients and 3,242 non-diabetic patients from the ARRIVE registry program. Due to significant disparity in baseline characteristics between diabetic and non-diabetic patients, propensity score analysis was used to allow for adjustment of baseline differences (other than the presence of diabetes) between the two groups.
The results showed diabetic patients had the well-known higher overall adjusted one-year mortality rate than patients without diabetes (3.7% vs. 2.3%, respectively, p=0.016), with the difference being driven by the cardiac death rate (2.3% vs. 1.2%, p=0.014), and reflecting the more advanced cardiac disease associated with diabetes. However, this difference was not related to the TAXUS Stent as the TAXUS Stent-related cardiac death rates at one-year were comparable in diabetics and non-diabetics, respectively (1.0% vs. 0.7%, p=0.29) in this patient population(2). Additionally, TAXUS Stent-related MCE rates (cardiac death, MI, and re-intervention) at one year were comparable (5.7% vs. 5.6%, p=0.80), as was the incidence of TAXUS Stent-related MI (1.6% vs. 1.2%, p=0.26), in both groups. Stent thrombosis at one year was low and showed no significant difference between diabetics and non-diabetics under Protocol definition (1.5% vs. 1.3%, p=0.59) or ARC Definite/Probable (1.7% vs. 1.2%, p=0.29). Unadjusted one-year rates of TAXUS Stent-related cardiac death, TAXUS Stent-related MCE, TAXUS Stent-related MI, and protocol-defined stent thrombosis showed no differences between the two populations (p-values of 0.30, 0.74, 0.31, and 0.65, respectively), suggesting that the safety profile is comparable for the two groups despite increased underlying risk in patients with diabetes. Additionally, the ARRIVE analysis confirmed that the TAXUS Stent maintained comparable re-intervention rates in the diabetic and non-diabetic patient populations in ARRIVE 1 and 2. Rates of one-year TVR, whether adjusted or unadjusted, were similar between the patient groups (6.1% vs. 6.0%, p=0.80, adjusted). TAXUS Stent-related re-intervention of a target vessel (equivalent to target lesion revascularization, or TLR) was also similar between the patient groups (4.3% vs. 4.5%, p=0.70), despite the known higher risk for re-intervention in diabetic patients. "The ARRIVE diabetic subset data demonstrated that the TAXUS Stent mitigated the adverse effect of diabetes as a risk factor for restenosis and repeat procedures in the patients studied," said Dr. Morris of the Albert Einstein Medical Center in Philadelphia, PA. "While the diabetic patients had more cardiac risk factors and co-morbidities than non-diabetics, the TAXUS- related cardiac death, MI and stent thrombosis in the ARRIVE 1 and 2 registries were similar in both groups, even without adjustment for risk factors." "Our extensive ARRIVE registries provide valuable insights into diabetic patients who are often at higher risk for mortality and repeat stenting procedures," said Paul LaViolette, Chief Operating Officer at Boston Scientific. "The ARRIVE data demonstrated that the TAXUS Stent neutralized diabetes as a risk factor for clinical restenosis in the patients studied." The growing diabetic subset accounts for more than one-quarter of all coronary interventional procedures in the United States. Diabetes is generally associated with an increased risk of cardiovascular events and patients with diabetes are more likely than non-diabetic patients to require repeat procedures due to a higher incidence of restenosis following angioplasty and stenting. The safety and effectiveness of the TAXUS Express Stent has not been established in patients with diabetes in the United States. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
01-Apr-2008 01:03
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Endeavor(R) Stent Safety Profile Affirmed in Long-Term Experience Saturday March 29, 9:02 am ET MINNEAPOLIS--(BUSINESS WIRE)--According to new data released today at the American College of Cardiology meeting, Medtronic?s Endeavor drug-eluting stent has a safety profile more commonly associated with a bare-metal stent, long considered a benchmark for stent safety. This latest extension to our pooled safety analysis of data from the ENDEAVOR clinical program nearly doubles the number of Endeavor patients followed to three years and therefore strengthens our confidence in the findings we presented previously,? explained Dr. Laura Mauri, chief scientific officer of the Harvard Clinical Research Institute, an interventional cardiologist at the Brigham and Women?s Hospital (both in Boston) and the lead author of the research. ?With more than 1,200 patients whose clinical follow-up now extends to three years, the Endeavor drug-eluting stent continues to be associated with low rates of stent thrombosis, myocardial infarction and cardiac death ? three key safety metrics ? compared to the Driver® bare-metal stent. Importantly, there were no new stent thrombosis events among patients in either group.?
Launched by Medtronic (NYSE:MDT - News) in the United States in February, the Endeavor stent is designed to promote rapid, complete and functional healing of the endothelium so that late safety concerns are minimized. It features an advanced cobalt alloy in a modular architecture for excellent deliverability and conformability, the antiproliferative drug zotarolimus to moderate neointimal hyperplasia, and a highly biocompatible polymer called phosphorylcholine (PC) for rapid drug elution. The independent analysis performed by Dr. Mauri and colleagues ? ?The Endeavor Zotarolimus-Eluting Stent in Patients with Native Coronary Artery Disease: Safety with 1,200 Patients Followed to Three Years? (2900-104) ? included a total of 2,132 Endeavor patients and 596 Driver patients. The following table presents the cumulative incidence of adverse safety events, as well as adherence to dual-antiplatelet therapy, in both groups to three years of follow-up:
? ARC = Academic Research Consortium; international group that developed standard definitions for stent thrombosis to use across all trials of drug-eluting stents ?? among patients in ENDEAVOR I, II, II continued access (CA), and III As summarized in the table, the rate of stent thrombosis (ARC definite/probable) before and after one year differed between the two groups, while adherence to dual-antiplatelet therapy was similar. Originally presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in October 2007, the pooled safety analysis is based on data from three of the ENDEAVOR clinical program?s single-arm studies (ENDEAVOR I, II continued access, and pharmacokinetics) and its three randomized controlled trials (ENDEAVOR II, III and IV). It now includes 2,050 Endeavor patients followed to one year, 1,287 followed to two years, and 1,217 to three. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maxximo
Member |
01-Apr-2008 00:59
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
BIG cheong ..... ???? If BIG price cheong this coming weeks .... it may be people anticipating a better than expected result annoucing soon ..... and some positive news will flow together with the result annoucement. Anyone know when likely is the result annoucment date for the closing of FY08 result??? If base on last year as reference, it will be sometime in late May .... then righfully action may take place only mid April wat ... (just my guess) .... Anyway, BIG is just too volalite .... unless u are on it full time, if not ... how to follow .... Bo pian ... wait lor ... hopefully the light is coming out of the tunnel soon ...... Cheers. Above not an inducement to trade. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
01-Apr-2008 00:58
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
12-Month Data From ENDEAVOR IV Show Strong Clinical Efficacy of Medtronic's Drug-Eluting Stent Across All Patient Groups Sunday March 30, 3:15 pm ET CHICAGO--(BUSINESS WIRE)--Data showing strong clinical efficacy for Medtronic?s Endeavor® drug-eluting stent were presented today at the American College of Cardiology meeting. Entitled ?One-Year Clinical and Angiographic Results in Diabetics from ENDEAVOR IV: A Randomized Comparison of the Endeavor Drug Eluting Stent System Versus Taxus in de novo Native Coronary Lesions? (2803-8) ? the presentation featured an analysis of 477 diabetic patients from the ENDEAVOR IV clinical study. ENDEAVOR IV is an ongoing head-to-head comparison of the Endeavor and Taxus stents in 1,548 patients. Below is a summary of the principal findings for the diabetic subset:
The safety and effectiveness of the Endeavor stent have not been established in diabetic patients. Data would first require both FDA review and approval. ?Performance of drug-eluting stents in diabetic patients is scrutinized by doctors because diabetes complicates so many aspects of the angioplasty procedure. Achieving good efficacy is more difficult, and safety concerns are significantly increased.? said Dr. Jeffrey Popma, Director of Invasive Cardiovascular Services, Caritas Cardiovascular Center for the Caritas Saint Elizabeth?s Medical Center in Boston, and director of the core lab that performed the angiographic analysis for the entire ENDEAVOR clinical program, including ENDEAVOR IV. Launched in the United States in February and now available in more than 120 countries worldwide, the Endeavor stent is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of ≥ 2.5 mm to ≤ 3.5 mm. Impact of angiography on TLR reinforced Also presented at the ACC scientific session were the findings of two other substudies from the ENDEAVOR IV clinical trial. One analysis ? ?The Impact of Mandatory Angiographic Follow-up on the One-Year Clinical and Angiographic Results From Endeavor IV: A Randomized Comparison of the Endeavor Drug Eluting Stent System vs. Taxus in De Novo Native Coronary Lesions? (2900-103) ? illustrated the artificial impact of routine angiography on revascularization rates. The first 328 enrolled ENDEAVOR-IV patients were selected to undergo angiography immediately post-procedure and again after eight months. These results were compared to the subsequent 1,200 patients in whom angiography was not performed. In patients receiving angiographic follow-up, the TLR rate at 12 months was 8.5 percent for Endeavor and 3.0 percent for Taxus but with no angiographic follow-up, the TLR rates were 3.6 percent for Endeavor and 3.3 percent for Taxus. These findings support the ARC recommendations that PCI clinical studies assess lesion characteristics with angiography only after the follow up required to assess the primary clinical endpoint. Side-branch occlusion with Endeavor A second sub-analysis ? ?The Fate of Side-Branches Among Patients Treated With Zotarolimus-Eluting and Paclitaxel-Eluting Stents: An ENDEAVOR-IV Substudy? (2901-19) ? looked at side-branch occlusion post-stenting. The analysis was conducted as doctors seek to explain the significantly increased rate of periprocedural MI with Taxus when compared to Endeavor observed in the ENDEAVOR IV clinical trial.
The ENDEAVOR IV clinical trial was not prospectively designed to evaluate side-branch occlusions, so further study is warranted. ENDEAVOR IV is evaluating 1,548 patients at 80 clinical centers in the United States, with a primary endpoint of Target Vessel Failure (TVF) at nine months and a secondary endpoint of Major Adverse Cardiac Events (MACE) at 30-days. The principal investigator is Dr. Martin B. Leon of Columbia University Medical Center and the Cardiovascular Research Foundation in New York. ENDEAVOR IV is evaluating 1,548 patients at 80 clinical centers in the United States, with a primary endpoint of Target Vessel Failure (TVF) at nine months and a secondary endpoint of Major Adverse Cardiac Events (MACE) at 30-days. The principal investigator is Dr. Martin B. Leon of Columbia University Medical Center and the Cardiovascular Research Foundation in New York. The Endeavor drug-eluting stent is made of a cobalt alloy and is built on the same platform as Medtronic?s popular Driver bare metal stent, which features a unique modular architecture designed to enhance deliverability. In addition to the cytostatic drug zotarolimus, Endeavor is coated with phosphorylcholine (PC) technology, a polymer designed to simulate the outside surface of a red blood cell and mimic the structure of the natural cell membrane. The combination of these components is designed to contribute to rapid, complete and functional healing of the endothelium. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
01-Apr-2008 00:55
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years Monday March 31, 9:00 am ET CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out to two years, including an observed 40 percent reduction in major adverse cardiac events (MACE) and an observed 44 percent reduction in vessel retreatment (ischemia-driven target lesion revascularization, TLR) compared to the TAXUS® paclitaxel-eluting coronary stent system. The two-year results from the SPIRIT II trial were presented at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit.
SPIRIT II is a 300-patient randomized clinical trial, which was conducted in Europe and Asia Pacific to support the launch of XIENCE V outside the United States. In SPIRIT II, XIENCE V demonstrated the following key results: -- In an analysis of major adverse cardiac events (MACE), XIENCE V demonstrated an observed 40 percent reduction in MACE compared to TAXUS at two years (6.6 percent for XIENCE V vs. 11.0 percent for TAXUS). MACE is an important clinical measure of patient outcomes, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization. -- XIENCE V demonstrated an observed 44 percent reduction in ischemia-driven target lesion revascularization (TLR driven by lack of blood supply) compared to TAXUS at two years (3.8 percent for XIENCE V vs. 6.8 percent for TAXUS). -- Rates of definite/probable stent thrombosis under the Dublin/Academic Research Consortium (ARC) definition were 0.9 percent for XIENCE V and 1.4 percent for TAXUS at two years. The ARC definition of late-stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials. "In clinical endpoints such as major adverse cardiac events, retreatment and heart attack, patients treated with XIENCE V in the SPIRIT II clinical trial continue to fare better than patients treated with TAXUS out to two years," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, and principal investigator of the SPIRIT II clinical trial, who presented the results today. "XIENCE V is performing as we would expect a next-generation drug eluting stent should over the long term, specifically on the important clinical endpoint of MACE. The low rate of MACE with XIENCE V compared to TAXUS was present at 6 months, one year and now at two years in the SPIRIT II trial." In a small subset of patients in the SPIRIT II trial, in-stent imaging results were evaluated at two years. In this 117-patient subset, the angiographic in-stent late loss rate was 0.33 mm for XIENCE V and 0.34 mm for TAXUS at two years. In-stent late loss is a measure of vessel renarrowing within the margins of the stent. "At any given point in time, across both the pivotal SPIRIT II and SPIRIT III clinical trials, XIENCE V consistently reduces observed MACE rates by 40 percent or more compared to TAXUS," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "The single-digit MACE rate seen with XIENCE V out to two years is encouraging data for interventionalists as they look for ways to improve patient outcomes with next-generation drug eluting stents." XIENCE V was launched in Europe and other international markets in late 2006. XIENCE V is an investigational device in the United States and Japan, and is currently under review for approval by the U.S. Food and Drug Administration. Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
01-Apr-2008 00:51
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage Sunday March 30, 2:30 pm ET CHICAGO--(BUSINESS WIRE)--Long-term, follow-up data presented today suggest that patients who received the CYPHER® Sirolimus-eluting Coronary Stent for blockage of a bare metal stent were significantly less likely to need another procedure (target lesion revascularization or TLR) at three years compared to patients who received brachytherapy. In addition, there were no significant differences in safety endpoints, such as the rates of death, myocardial infarction (MI), or stent thrombosis between the two treatment arms of this study.
These data were presented at the Society for Cardiovascular Angiography and Interventions (SCAI) Annual Scientific Sessions in Partnership with American College of Cardiology (ACC) i2 Summit during the 57th Annual Scientific Sessions.
The SISR Trial (A Randomized Trial Comparing Sirolimus-Eluting Stent with Vascular Brachytherapy for the Treatment of In-Stent Restenosis Within Bare Metal Stents) is a multi-center, randomized study of 384 patients from 26 academic and community health centers in the United States. The original trial was designed for follow-up at nine months. This longer-term, follow-up analysis focused on pre-specified safety endpoints, namely death, MI and stent thrombosis, as well as target lesion revascularization (TLR), an efficacy endpoint, to determine whether any new safety issues emerged and whether the major benefit of the CYPHER® Stent, namely reduction in TLR, was maintained. Cordis Corporation sponsored the trial. ?These data continue to favor the CYPHER® Stent compared to radiation therapy in these patients with complex coronary artery disease,? said David R. Holmes Jr., M.D., Principal Investigator and Professor of Medicine, The Mayo Clinic College of Medicine, Rochester, MN. ?Neither treatment modality in this study was associated with any new safety issues or concerns.? Dr. Holmes also serves as an advisory board member to the company?s e-SELECT registry, which is being conducted outside the United States. At three years, 81 percent of patients who received the CYPHER® Stent were free from a TLR compared to 71.6 percent of patients receiving brachytherapy (p=0.018). For target vessel revascularization, the survival free rates were 78.2 percent for the CYPHER® Stent and 68.8 percent for the brachytherapy arm (p=0.022). The stent thrombosis rates, as defined as definite and probable per the Academic Research Consortium (ARC) definitions, were not significantly different (3.7 percent for the CYPHER® Stent vs. 2.6 percent for brachytherapy; p=0.606). Although three year rates of target vessel failure (the CYPHER® Stent, 75.1 percent; brachytherapy, 67.9 percent; p=0.067) and major adverse cardiac events, also known as MACE, were both improved with the CYPHER® Stent, this did not reach statistical significance, likely reflecting progression of coronary artery disease at sites other than the original location of bare metal stent restenosis. Rates of MACE were 75.5 percent for the CYPHER® Stent and 70.5 percent for brachytherapy (p=0.186). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
01-Apr-2008 00:44
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Drug-Coated Stents Safe for Heart Attack Patients, Study Finds By Michelle Fay Cortez March 30 (Bloomberg) -- Drug-coated stents are safe for heart attack patients and may improve their chances of survival, according to research presented at a medical meeting. Patients who get the devices to prop open their clogged heart arteries need to take pills for a year to prevent deadly blood clots from developing. While many doctors use drug-coated stents made by Boston Scientific Corp., Johnson & Johnson and Medtronic Inc., others have cut back for fear that some heart attack patients won't consistently take the anti-clot medicine. A database of 7,216 patients in Massachusetts found those who got the drug-coated devices were less likely to need repeat procedures or die than those getting older bare-metal stents, and rates of heart attacks caused by clots were similar. A second study from Italian researchers found major heart complications were cut in half with drug coated devices. ``Although neither bare-metal stents nor drug-eluting stents were originally approved in the setting of heart attacks, it is probably the most important condition we treat with stents,'' said Laura Mauri, chief scientific officer of the Harvard Clinical Research Institute in Boston. ``I would feel comfortable considering drug-eluting stents on the basis of these results,'' providing patients take their drugs, she said. The studies were presented today at a joint meeting of the Society for Cardiovascular Angiography and Interventions and the American College of Cardiology in Chicago. Coating Concern The drug-coating on the devices may impair healing of the artery, which is already inflamed and may be prone to clots, said Paul Gurbel, director of cardiovascular research at Sinai Hospital of Baltimore, in an interview. Still, many doctors use them because they are known to reduce the need for retreatment, he said. In Mauri's study, 15.5 percent of patients getting drug- coated stents needed a repeat procedure within two years to clear their arteries, compared with 20.8 percent of those with older, bare-metal devices. Death rates were 10.4 percent in the drug-coated patients, versus 13.2 percent in the older group. The second study compared the two types of stents in 745 heart attack patients in Italy, Spain and Argentina. After eight months, 7.8 percent of patients getting Johnson & Johnson's Cypher died, had a repeat heart attack or needed retreatment, compared with 14.5 percent of those getting an uncoated stent. The number of late stent blockages in the two groups was similar. Patients also received Bristol-Myers Squibb Co. and Sanofi- Aventis SA's Plavix for at least three months. The study was funded by Merck & Co., which developed a drug used during the procedure to implant the stents. Sales Decline U.S. sales of drug-coated stents plunged 37 percent in 2007 after studies suggested patients may unexpectedly form the dangerous blood clots that block the devices more than a year after they are implanted. Other research last year found aggressive drug therapy may treat chronic chest pain just as well as the permanently implanted devices, reducing their use. The two studies and other recent findings suggest doctors might have gone too far in reducing their use of drug-coated stents, said Magnus Ohman, director for advanced coronary disease at Duke University Medical Center. The overall death rate would include those caused by the clots, known as late- stent thrombosis, and a reduction is encouraging, he said. ``This is provocative data,'' said Ohman, who wasn't involved in the study, in an interview. ``Maybe we overshot.'' To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ykjuay
Senior |
01-Apr-2008 00:14
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
tmr will run, juz watch | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
jasonrxz
Senior |
31-Mar-2008 22:36
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Hi to all BIG supporters, Today while all counters are having retreats ( profit takings) after a few session of window dressing , this baby still been support by alot of believers and i really hope and know that this counter will move in big steps in days to come... i saw that the buy up are really in huge amount and let's prepare for a rocket ride ok? it's just my feel that it will and this feel is really strong though.... hope i am right... cheers |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
zhenxian
Senior |
31-Mar-2008 22:13
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
haha ok. hmm.. will it be possible another better product like this suddenly pop out from other company then hor sey liao. but i am still vested though :) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
allright
Senior |
31-Mar-2008 19:53
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
I have my old stock and recent purchase...the first few at high price of .885...I will hold onto the shares but was thinking of picking a few more. Thanks AK Francis . I was told by my broker to wait until the price start moving up before going in...but always listen to him and end up buying at the high because the price doesnt hold...BUT I AM VERY PATIENT and believe we will have the LAST LAUGH... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AK_Francis
Supreme |
31-Mar-2008 18:10
Yells: "Happy go lucky, cheers." |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Allright, you still can buy the burger when the price slided again, how much, thats you have to follow it closely with its related business news leow. If there is potential for it to cheong, then waiting for the price to slide may note be the strategy. I still keeping 60 lots of it, as I may buy in further to do the avg. Hope BS more good yr to come, cheers. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XiaoMaGe888
Senior |
31-Mar-2008 18:06
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Closing 0.735 BUY UP Tomolo sure CHIONG!!!!!!!!!!!!!!!!Xiao BIG!!!!!!!!!!!!123UP!!!UP!!!!UP!!!!!!!! |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
allright
Senior |
31-Mar-2008 17:55
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Hahaha thanks Ak Francis....I realised that ...but it was good to note that the others are still positive on the takeover...I had given up hope on that as everyone was so quiet and so relied on the trading of the share | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AK_Francis
Supreme |
31-Mar-2008 17:45
Yells: "Happy go lucky, cheers." |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Sorry, I was referred to brother Allright whether BS will reach 0.88, I meant will be coming to hit 0.8xxx. Kancheong lah, as I need to flip bt this forum and online trading, ha ha. As for other advices no $2.00 and above no sell. They are very courages. According to last coy report, BS will likely see profit in mid 2009. Hope there is changes on their balance sheet, lately. Cheers. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bengster68
Master |
31-Mar-2008 16:31
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Takeover will be $3. No $3 no sell. BIG, China JWMS and BIG's group of Biolimus/PLA biodegredable polymer gang will eat up their market share. If they want to ensure market dominance, only by having the best DES technology then can make it. With BIG's technology and patents in their pocket, this is the best weapon any DES major can ever ask for. ABT paid US$4.1B for Xience DES. Xience is not the best DES, has blood-clot problems and no patent fencing. If BIG remains independent, this stock will cross $3 in 2011 after FDA approval is obtained for Biomatrix. USA market will shrink in comparison to global consumption of DES. This is because USA is a matured market while 3rd world countries are experiencing explosive new demand for DES. This is why China JWMS is very crucial to become a true global DES powerhouse. Cheap and good export grade DES backed by massive and proven 2,000 patient CREATE clinical trial. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
novena_33
Veteran |
31-Mar-2008 16:15
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
maybe can sell higher lar.... now US will kenah recession soon....sure more ppl need their product | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XiaoMaGe888
Senior |
31-Mar-2008 15:11
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
How? Dun sell lah ,Bro. No $2 dun sell |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
zhenxian
Senior |
31-Mar-2008 14:36
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x 0
x 0 Alert Admin |
under such market condition, if the take over price is below $0.80 how? Cause they can offer any price that is higher then current price right? wah like that, then those bought at $1 will sure lose one. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Useful To Me Not Useful To Me |